Opinion|Videos|February 21, 2024
Advancements in Hemophilia A Therapies
Steven W. Pipe, MD, explores the latest developments in hemophilia A treatments and prophylactic therapies, including extended half-life agents and a groundbreaking bispecific antibody.
Episodes in this series
This is a video synopsis/summary of an Insights featuring Steven W. Pipe, MD.
In this insightful discussion with Pipe, the focus is on evaluating current and emerging therapies for hemophilia A. The conversation delves into the classes of prophylactic treatment available, specifically highlighting 2 distinct strategies: factor replacement therapy and substitution therapy. Pipe elucidates the evolution of factor replacement products, spanning legacy standard half-life agents to Altuviiio, a high-sustained factor VIII replacement therapy with a once-weekly dosing strategy. The extended half-life agents, utilizing recombinant platforms with modifications, have shown considerable progress in reducing the treatment burden. Notably, Altuviiio maintains normal to near-normal factor VIII levels for an extended period after treatment. The discussion also introduces substitution therapy, featuring a humanized bispecific antibody with a prolonged half-life of about 30 days. This therapy mimics the action of activated factor VIII, providing steady-state hemostatic correction, administered subcutaneously for added patient convenience. The overall exploration underscores the transformative impact of these therapies, not only in altering pharmacokinetics but also in enhancing patient experience by minimizing venous access challenges and optimizing treatment efficacy.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Related to this article
At a Stakeholder Interchange convened by The American Journal of Managed Care® in Tampa, Florida, an academic-community mix of hematologist-oncologists and pharmacists debated prior authorization, site-of-care payment disparities, and how aggressively to push bispecific antibody regimens to community practices treating patients with relapsed/refractory multiple myeloma.
Portuguese patch testing finds many chronic hand eczema cases link to allergic contact dermatitis—especially occupational exposures like methylisothiazolinone, HEMA acrylates, thiuram mix, nickel.
The National Comprehensive Cancer Network update on mantle cell lymphoma puts covalent BTK inhibitors, MRD testing, and TP53 sequencing at the center of frontline care, while adding pirtobrutinib and a pair of CAR T-cell therapies for disease that progresses on a BTK inhibitor.
These findings demonstrate substantial but variable use of community care consultations for specialty care among patients with diabetic foot ulcers within the Veterans Health Administration.
Two posters report 3.9% first-year GLP-1 discontinuation and a 5-day median time to first fill under pharmacist-led care.
CDC's Jane Henley, MSPH, explains what's behind falling lung cancer deaths and why 4 in 5 eligible adults still aren't getting screened.
The regulatory decisions reflect how advances in biomarkers and molecular medicine are reshaping both diagnosis and treatment.
Measles cases hit a year high. Here's what payers need to know about outbreak costs, MMR coverage, and plans to split the vaccine
Trending on AJMC
1
NCCN Journal Publishes Guidelines Update in Mantle Cell Lymphoma
2
Peptide Regulation Debate Intensifies After FDA Advisory Panel's Controversial Vote
3
Switching to Subcutaneous Ocrelizumab for MS Could Free 883 Chair Hours in a Year
4
Why 4 in 5 Eligible Adults Miss Lung Cancer Screening
5